Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Xencor
Biotech
Xencor pulls back from Genentech cancer pact to cut costs
Xencor and CytomX have taken a scalpel to their pipelines, stopping work on an ex-AbbVie ADC and pulling back from a Genentech co-development deal.
Nick Paul Taylor
Nov 8, 2023 6:00am
BMS pays Zenas $50M for some rights to ex-Xencor autoimmune drug
Sep 5, 2023 7:29am
Zenas zips up $118M series B to launch phase 3 trial
Nov 8, 2022 11:35am
Xencor culls 2 bispecifics after early-phase data underwhelm
May 6, 2022 8:30am
Xencor sells ex-lead drug to Tesaro founder in backloaded deal
Nov 22, 2021 8:45am
Novartis dumps 2nd bispecific from $2.6B Xencor pact
Nov 9, 2021 8:20am
